‘LEFOXIN BIOX’ vs ‘LANOXIN’: Bombay HC Expunges Junior Mark

In Glaxo Group Limited Vs Shreya Life Sciences Private Limited [COMMP/12/2026], the Bombay High Court expunged Respondent No. 1’s registered trade mark ‘LEFOXIN BIOX’ (Registration No. 5001470) in Class 5 under Section 57 of the Trade Marks Act, 1999, upholding the statutory priority and public health protection undergirding Petitioner’s legacy mark ‘LANOXIN’ registered since 1956. Justice Somasekhar Sundaresan firmly rejected the defense that exclusive export manufacturing insulates a junior mark from rectification under Section 11(1)(b), holding that Section 56(1) deems export usage to be statutory use within India, thereby confirming that maintaining a deceptively similar mark on the Register constitutes an unmitigated public mischief regardless of current territorial sales distribution.

The Jurisdictional Threshold of ‘Person Aggrieved’ and Public Interest in Register Purity

New to Indian Trademark Law? Start with our comprehensive Trademark Law Guide.

The preliminary skirmish in trademark rectification frequently centers on standing under Section 57(2) of the Trade Marks Act, 1999. Respondent No. 1 contended that Petitioner was not a “person aggrieved”, alleging that because Respondent’s Levofloxacin antibiotic tablets were manufactured solely for export to overseas markets such as Russia, Ukraine, and Kazakhstan, no commercial injury or consumer confusion could materialize within Indian territory. This argument sought to draw support from narrow interpretations of commercial rivalry.

Justice Somasekhar Sundaresan dismantled this defense by situating Section 57 within its proper doctrinal framework. Citing the Supreme Court authority in Hardie Trading Ltd. v. Addisons Paint & Chemicals Ltd. (2003) 11 SCC 92, alongside Infosys Technologies Ltd. v. Jupiter Infosys Ltd. (2011) 1 SCC 125 and Kabushiki Kaisha Toshiba v. Toshiba Appliances Co. (2008) 10 SCC 766, the High Court reaffirmed that the locus standi threshold under Section 57 for expunging an entry wrongly made or remaining on the Register is significantly broader than the non-use removal standards under Section 47. Section 57 actions are instituted to maintain the purity of the Register, an imperative anchored firmly in public interest.

Emphasizing that the proprietor of a senior registered mark in the same therapeutic class cannot be treated as an officious intermeddler or busybody, the Court articulated the threshold principle governing statutory standing:

Evidently, Glaxo owns an earlier registration for LANOXIN in Class 5 for a pharmaceutical product. The mark is phonetically and visually somewhat similar and also used in the same field, although applied to a different formulation, although such formulations with the respective brand names are marketed in different markets. In view of the statutory protection available through the Impugned Registration, Glaxo would be entitled to pursue, on merits, its request for rectification. I am not satisfied that Glaxo is a complete third party with no locus for its case to be shut out at the threshold.

Hon’ble Mr. Justice Somasekhar Sundaresan, Bombay High Court

This holding reinforces that an existing registrant whose legal rights are limited or potentially threatened by a junior registration possesses unimpeachable standing to initiate rectification proceedings, irrespective of whether immediate domestic market overlap has manifested.

Anti-Dissection versus Dominant Feature Test: Deceptive Similarity in Pharmaceutical Marks

The substantive crux of the dispute required comparing Glaxo’s senior mark ‘LANOXIN’ against Shreya’s registered mark ‘LEFOXIN BIOX’ under Section 11(1)(b). Respondent invoked Section 17 of the Trade Marks Act, 1999, advocating a rigid application of the anti-dissection rule. Shreya asserted that ‘LEFOXIN BIOX’ was a composite mark comprising two distinct words, where ‘BIOX’ provided descriptive distinctiveness referencing biological oxidation, and that the prefix ‘LEF’ differed fundamentally from ‘LAN’. Shreya further argued that the suffix ‘OXIN’ was common to the pharmaceutical trade to denote fluoroquinolone compounds, disentitling Glaxo from claiming exclusivity over it.

The Court navigated the delicate interplay between the anti-dissection rule and the dominant feature doctrine. While trade marks must be judged as structural wholes when evaluated through the eyes of a consumer of average intelligence and imperfect recollection, courts cannot ignore the dominant, structural nucleus of a mark. The Bench held that ‘LEFOXIN’ constituted the primary visual and structural element of the impugned mark, while ‘BIOX’ functioned merely as a descriptive suffix or line-extension modifier. Rather than creating distinctiveness, appending ‘BIOX’ to ‘LEFOXIN’ creates the impression that the product is simply a specialized line extension or biological variant of the senior ‘LANOXIN’ brand.

Furthermore, the Court rejected Respondent’s “common to the trade” defense regarding the suffix ‘OXIN’. On evidentiary analysis, Glaxo demonstrated that out of sixteen competing Levofloxacin brands operating in the Indian market, only one single third-party brand utilized the suffix ‘OXIN’. Under established jurisprudence, to establish that a prefix or suffix is publici juris, a litigant must submit cogent, extensive evidence demonstrating widespread commercial adoption and actual market presence of multiple third-party marks utilizing that element. Mere registry entries without evidence of active market usage fail to establish that a term is common to the trade.

Evaluating the pharmaceutical context, the Court applied the heightened standard established by the Supreme Court in Cadila Healthcare Ltd. v. Cadila Pharmaceuticals Ltd. (2001) 5 SCC 73 and affirmed by the Bombay High Court Division Bench in Macleods Pharmaceuticals Ltd. v. Union of India (2023 SCC OnLine Bom 408). In medicine, deceptive similarity carries grave public health hazards. Respondent argued that because LANOXIN consists of Digoxin (prescribed for cardiac failure and supraventricular arrhythmias) while LEFOXIN BIOX consists of Levofloxacin (a broad-spectrum antibiotic), the distinct Active Pharmaceutical Ingredients (APIs), medical indications, and prescription-only distribution channels eliminated confusion. The High Court decisively rejected this proposition. Where trade marks are deceptively similar, the fact that the underlying drugs cure completely different medical conditions heightens the danger of confusion, as an accidental substitution of a cardiac drug with a potent antibiotic can produce fatal consequences for a patient.

Statutory Fiction under Section 56: Neutralizing the Export-Only Defense

The pivotal legal ruling in this judgment concerns the interplay between territorial usage and statutory deeming fictions under Section 56(1) of the Trade Marks Act, 1999. Shreya contended that its operations were confined strictly to manufacturing Levofloxacin tablets in Aurangabad for export to foreign jurisdictions, offering to submit a formal undertaking to never market products under the impugned mark within India. Respondent argued that export activities could not generate consumer confusion among Indian doctors or patients.

Justice Sundaresan dismantled this operational defense by enforcing the plain language of Section 56(1). The statute explicitly mandates that the application of a trade mark in India to goods intended for export, or any other act performed in India regarding export goods, shall be deemed to constitute use of the trade mark for any purpose for which use is material under the Act or any other law.

Citing the binding Division Bench ruling in Cadila Pharmaceuticals Ltd. v. Sami Khatib of Mumbai (2011 SCC OnLine Bom 484), the Court established that export manufacturing in India is statutorily equivalent to domestic commercial use. The Bench observed:

Therefore, even if the mark is used essentially for exports, under Section 56(1) of the TM Act, it would follow that the use would constitute use of the mark in India. Therefore, application of the Impugned Mark on pharmaceutical products to be exported from India is, in the eyes of law, use of the trade mark in India.

Hon’ble Mr. Justice Somasekhar Sundaresan, Bombay High Court

This statutory fiction carries profound consequences for rectification proceedings. An entry that breaches Section 11(1)(b) at the time of application or registration cannot be saved by an undertaking restricting physical sales to foreign territories. Because export manufacturing constitutes statutory trademark use within India under Section 56(1), a junior registrant cannot bypass statutory prohibitions on confusingly similar entries by operating an export-only business model.

This finding harmonizes with the constitutional and statutory framework governing registered trade marks. Under Section 28(1), registration grants exclusive statutory rights to use the mark. However, as established in S. Syed Mohideen v. P. Sulochana Bai (2016) 2 SCC 683 and Neon Laboratories Ltd. v. Medical Technologies Ltd. (2016) 2 SCC 672, registration under Section 28 does not confer absolute immunity against a prior registered proprietor or senior user. When a junior registration is challenged under Section 57, the statutory fiction of Section 56(1) ensures that export-oriented junior marks remain fully amenable to the purity standard of the Register.

Litigator’s Playbook: Section 57 Rectification versus Section 134 Infringement Strategy

For intellectual property litigators, this judgment illuminates key tactical considerations when determining whether to initiate rectification proceedings under Section 57 before the High Court or file an infringement suit under Section 134 read with Section 29.

1. Bypassing the Interlocutory Injunction Triple Test: In standard infringement suits under Section 134, securing temporary injunctions under Order XXXIX Rules 1 and 2 of the Code of Civil Procedure, 1908 requires satisfying the tripartite test articulated in Wander Ltd. v. Antox India P. Ltd. (1990 Supp SCC 727): establishing a prima facie case, demonstrating balance of convenience, and proving irreparable injury. Where a defendant operates exclusively in export markets or claims non-interfering trade channels, courts frequently hesitate to grant interlocutory injunctions due to perceived lack of immediate domestic market harm. Conversely, a Section 57 rectification petition focuses strictly on the statutory validity and purity of the Register under Sections 11, 18, and 57. Questions of domestic commercial injury, delay, or balance of convenience do not override clear statutory bars against confusing registrations.

2. Evidentiary Forensics in Section 57 Proceedings: Petitioners challenging junior registrations must build robust evidentiary records to defeat common defenses:

• Evicting Common-to-Trade Claims: Litigators must execute comprehensive market surveys and Registry audits. To counter claims that structural prefixes or suffixes (such as ‘OXIN’) are generic, counsel must place certified sales data, IQVIA/IMS health market reports, and drug controller licensing databases on record to demonstrate that third-party usage is minimal or non-existent.
• Forensic Audit of Export and Digital Invoices: Petitioners must monitor shipping manifests, customs data, B2B e-commerce portals (such as IndiaMART or Alibaba), and overseas regulatory filings. Demonstrating that an Indian manufacturer applies the contested mark to goods within Indian factories triggers Section 56(1), effectively foreclosing export-only defenses.

Also Read: Delhi HC Restrains ‘VEEPRO’ Mark for Infringing ‘WIPRO’ Trademark

Corporate Strategy & Due Diligence Guidelines for In-House Counsel

This decision provides imperative operational guidance for corporate in-house legal teams overseeing pharmaceutical brand portfolios and international supply chains:

1. Eradicate the Export Immunity Fallacy: In-house counsel must dismantle the mistaken assumption that manufacturing drugs exclusively for foreign markets shields the enterprise from domestic trademark liability. Pre-launch clearance searches must be conducted against the Indian Trade Marks Registry with the same rigor regardless of whether the product is destined for domestic pharmacies or export shipments. If a proposed brand conflicts phonetically or visually with a senior Indian registration in Class 5, manufacturing within India exposes the corporation to rectification and statutory infringement under Section 56(1).

2. Deconstruct Secondary Modifiers and Prefix Integrity: Product development teams often attempt to differentiate brands by appending descriptive suffixes or prefix modifiers (such as ‘BIOX’, ‘PLUS’, or ‘FORTE’). Legal teams must advise business units that under dominant feature analysis, secondary descriptive modifiers rarely cure deceptive similarity if the structural prefix (‘LEFOXIN’ vs ‘LANOXIN’) closely mimics a senior mark. Brand creation protocols must mandate structural distinctiveness at the root word stage.

3. Proactive Watch Services and Section 57 Timelines: While failure to file a Notice of Opposition during the journal advertisement window under Section 21 does not bar a subsequent rectification petition under Section 57, delayed action enables respondents to build equity defenses. Implementing automated trademark journal monitoring ensures that conflicting marks are opposed at the pre-registration stage, avoiding costly High Court rectification litigation.